Search bioRxiv⌕ Search

Biology subjects

Hahn, S. A.

Publications and source records attributed to Hahn, S. A..

6 recordsLinked to original sources

CYB5R3 Controls Sex-Specific Stress Erythropoiesis via Heme-Biosynthesis

Cytochrome b5 reductase 3 (CYB5R3) or met-hemoglobin reductase is an oxidoreductase that maintains hemoprotein and cellular redox balance, yet its contribution to erythropoiesis under stress conditions remains unclear. Motivated by prior observations that the hypomorphic CYB5R3 T117S blunts hydroxyurea-induced fetal hemoglobin responses in patients with sickle cell disease, we tested whether CYB5R3 contributes to the regulation of erythropoiesis. Hematopoietic lineage-specific CYB5R3 knockout mice exhibited markedly impaired erythropoietic induction in response to chronic hypoxia compared to controls, with males showing a more pronounced deficit, and splenectomy further exacerbating this impairment. Genetic deletion of CYB5R3 in human CD34 progenitors reduced globin expression and disrupted terminal erythroid differentiation. Meanwhile, CYB5R3 knockdown in K562 cells produced a heme-deficient state whereby only exogenous heme but not hydroxyurea, iron, or upstream precursors restored globin synthesis. Transcriptomic profiling revealed coordinated downregulation of erythroid transcription factors and multiple enzymes in the heme biosynthetic pathway, which was reversed with heme treatment. Together, these results reveal an unexpected function for CYB5R3 beyond met-hemoglobin reduction, positioning it as a central metabolic regulator of sex-specific stress erythropoiesis and unveiling a heme-restricted vulnerability that may augment disease severity in anemia, hemoglobinopathies, and individuals carrying CYB5R3 loss-of-function variants. Key pointsO_LICYB5R3 is required for effective stress erythropoietic induction, with a more pronounced impact in males. C_LIO_LIErythroid-specific CYB5R3 deficiency creates a heme-limited state, impairing erythroblast differentiation and maturation. C_LI

molecular biology↗

Endothelial CYB5R3 couples store-operated calcium entry to TRPV2 activation and vascular fitness

NADH-cytochrome b5 reductase 3 (CYB5R3) is a flavoprotein that governs nitric oxide (NO) signaling and supports NADPH oxidase 4-derived hydrogen peroxide production via coenzyme Q reduction in endothelium. While CYB5R3 expression is decreased during aging, the downstream consequences of CYB5R3 loss are not understood. Here, we demonstrate that depletion of CYB5R3 in primary human aortic endothelial cells activates a Ca2+ influx network characterized by the upregulation of calcium release-activated calcium (CRAC) channel subunits ORAI2 and ORAI3, as well as the non-selective cation channel transient receptor potential vanilloid 2 (TRPV2). When endoplasmic-reticulum Ca2+ stores were depleted, CYB5R3-deficient cells had increased Ca2+ entry through the plasma membrane, part of which was insensitive to classical store-operated Ca2+ entry (SOCE) blockers and was mediated by TRPV2, as demonstrated by genetic knockdown and pharmacologic inhibition. Mechanistically, loss of CYB5R3 increased Ca2+-dependent NO production through elevated CRAC channel activity, which oxidatively inhibited the protein tyrosine phosphatase non-receptor type 1 (PTPN1). This prevented TRPV2 dephosphorylation, thereby maintaining Janus kinase 1 (JAK1)-dependent channel activation downstream of SOCE. It also enhanced the responsiveness of TRPV2 to physiological heat stimuli. Thus, CYB5R3 normally acts as a brake, limiting NO-dependent PTPN1 oxidation and restraining TRPV2 activity. In vivo, endothelial-specific Cyb5r3 deletion enhanced acetylcholine-induced vasorelaxation and improved exercise capacity, demonstrating a physiological function for this pathway in vascular adaptation. Together, these findings identify a CYB5R3-NO-SOCE- PTPN1-TRPV2 signaling axis that couples endothelial redox balance to Ca2+ dynamics and vascular function. SIGNIFICANCEEndothelial cells rely on receptor-regulated Ca2+ signals to produce vasodilators and control vascular function; however, the molecular mechanisms coordinating these pathways are incompletely understood. We identify CYB5R3 as a key redox switch that couples store-operated Ca2+ entry to the non-selective cation channel TRPV2. Loss of CYB5R3 enhances TRPV2 activity downstream of SOCE through NO-dependent oxidative inhibition of the phosphatase PTPN1, sustaining Janus kinase-mediated TRPV2 channel activation. This novel mechanism expands the physiological scope of CYB5R3 by redefining how redox enzymes intersect with Ca2+ signaling, linking endothelial CYB5R3 to vascular relaxation and exercise capacity in vivo. This positions CYB5R3 as a central regulator of vascular function with broad implications for cardiovascular health and disease.

cell biology↗

CYB5R4 sustains endothelial proliferation and ischemia-induced angiogenesis by maintaining RRM2-dependent nucleotide balance

Angiogenesis is essential for revascularization in peripheral artery disease (PAD), yet pro-angiogenic therapies remain inconsistent. Here, we identify a cytosolic reductase, CYB5R4, as an intrinsic regulator of endothelial proliferation and ischemia-induced angiogenesis. In mice, global haploinsufficiency or inducible endothelial deletion of Cyb5r4 delayed perfusion recovery after femoral artery ligation and reduced capillary expansion. CYB5R4 is known to promote stearoyl-CoA desaturase (SCD) activity and is required for the de novo synthesis of monounsaturated fatty acids. In human endothelial cells, CYB5R4 silencing impaired proliferation with G1-S arrest that was not rescued by monounsaturated fatty acids and differed from the loss of SCD, indicating an SCD-independent mechanism. RNA sequencing with Bayesian network inference highlighted the ribonucleotide-reductase subunit RRM2 as a key downstream mediator. RRM2 overexpression partially restored proliferation. Integrated untargeted metabolomics and targeted nucleotide quantification revealed an imbalanced nucleotide pool in CYB5R4-deficient cells. These findings support a model in which CYB5R4 sustains endothelial proliferation and ischemia-driven angiogenesis by maintaining RRM2-dependent nucleotide balance. Targeting the CYB5R4-RRM2 axis may improve therapeutic angiogenesis in PAD.

molecular biology↗

Development of an Open-source Low-cost Pressure Myography and Cardiac Flow Simulator, HemoLens, for Mechanical Characterization of Native and Engineered Blood Vessels

Pressure myography, the standard for assessing vascular mechanics and vasoreactivity, is costly ($40,000+), has low throughput, and is limited to static fluid flow. Here, we developed HemoLens, an open-source 3D-printed pressure myography system for [~]$700. HemoLens features compact micromanipulators, incremental in-line pressure control, physiological temperature regulation, and modular pulse pressure control between normotensive and hypertensive levels. HemoLens efficacy was demonstrated by delineation of physiological reactivity and pathological mechanical phenotypes using native mouse arteries and bioprinted acellular scaffolds. Wildtype vessels show greater distention (124.3 vs. 43.07 {micro}m) and increased dynamic compliance compared to diseased vessels. Small diameter (450 {micro}m) collagen-based artery-like scaffolds are FRESH bioprinted to mimic hypertensive vascular stiffening. Engineered hypertensive vessels demonstrate increased burst pressure (464 mmHg) and reduced dynamic compliance reminiscent of diseased arteries. Together, HemoLens lowers the barrier to entry in pressure myography research by serving as a comprehensive low-cost system for native and engineered vessel characterization. Graphical Abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=90 SRC="FIGDIR/small/651300v1_ufig1.gif" ALT="Figure 1"> View larger version (33K): org.highwire.dtl.DTLVardef@6b87d0org.highwire.dtl.DTLVardef@1a17b5eorg.highwire.dtl.DTLVardef@aa6056org.highwire.dtl.DTLVardef@19ac816_HPS_FORMAT_FIGEXP M_FIG C_FIG

bioengineering↗

Novel peptide targeting CXCR4 disrupt tumor-stroma crosstalk to eliminate migrating cancer stem cells

Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and metastatic malignancies worldwide. Migrating cancer stem cells (miCSCs) marked by CD133+CXCR4+ expression drives metastasis but lacks effective drug targets. Here, we show that activated pancreatic stellate cells secrete the CXCR4 ligand CXCL12 to foster stemness, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Protein interaction network analyses links CXCL12/CXCR4 signaling axis and the downstream transcription factor BMI1. Knockdown experiments confirmed the BMI1s role in (mi)CSCs maintenance and survival. Novel CXCR4 inhibitors, i.e., the endogenous human peptide EPI-X4 and its derivatives (e.g., JM#21) strongly inhibited the in vitro migration of miCSCs. In particular, the most potent EPI-X4 derivate JM#21 sufficiently suppressed EMT, stemness, and self-renewal of human PDAC cell lines. In addition, JM#21 sensitized cell lines towards gemcitabine and paclitaxel. Overall, our study reveals that (mi)CSCs are enhanced and maintained via a tumor-stroma crosstalk through BMI1, ultimately promoting metastases and therapeutic resistance in PDAC. Peptide targeting of the CXCL12/CXCR4/BMI1 signaling axis via JM#21 could enhance PDAC combination therapies, offering a promising strategy against this deadly cancer. SynopsisThe study identifies a tumor-stroma interaction mediated by pancreatic stellate cells (PSCs) secreting CXCL12, which binds to CXCR4 on (mi)CSCs, fostering stemness, epithelial-to-mesenchymal transition (EMT), and chemoresistance. The CXCL12/CXCR4 axis activates the downstream BMI1 transcription factor, crucial for migration and stemness maintenance. O_FIG O_LINKSMALLFIG WIDTH=173 HEIGHT=200 SRC="FIGDIR/small/641126v1_ufig1.gif" ALT="Figure 1"> View larger version (50K): org.highwire.dtl.DTLVardef@14e117org.highwire.dtl.DTLVardef@c5db35org.highwire.dtl.DTLVardef@1ba7d2dorg.highwire.dtl.DTLVardef@702ccf_HPS_FORMAT_FIGEXP M_FIG C_FIG O_LICXCL12 enhances (mi)CSC populations and metastatic potential through CXCR4 signaling. C_LIO_LIBMI1 is identified as a pivotal downstream effector linking CXCR4 to EMT and stemness. C_LIO_LIJM#21 effectively blocks CXCL12-induced migration, EMT, and stemness in vitro, demonstrating superior efficacy compared to other CXCR4 inhibitors. C_LIO_LIEncapsulation of JM#21 in silica nanoparticles enhances its stability and delivery, reducing chemoresistance and miCSC populations in co-culture systems. C_LIO_LICombining JM#21 with chemotherapy significantly impairs colony formation and CSC-mediated drug resistance. C_LI

cancer biology↗

Co-inhibition of topoisomerase 1 and BRD4-mediated pause release selectively kills pancreatic cancer via readthrough transcription

Pancreatic carcinoma is one of the most lethal cancers and the absence of efficient therapeutic strategies results in poor prognosis. Transcriptional dysregulation due to alterations in KRAS and MYC impacts initiation, development, and survival of this tumor type. Using patient-derived xenografts of pancreatic carcinoma driven by KRAS and MYC oncogenic transcription, we show that co-inhibition of Topoisomerase 1 (TOP1) and bromodomain containing protein 4 (BRD4) synergistically induce tumor regression through targeting promoter pause-release, a rate-limiting step in transcription elongation. By comparing the nascent transcriptome with the recruitment of elongation and termination factors along genes, we found that co-inhibition of TOP1 and BRD4, while globally impairing RNA production, disturbs recruitment of proteins involved in termination. Thus, RNA polymerases continue transcribing downstream of genes for hundreds of kilobases leading to readthrough transcription. This pervasive transcription also occurs during replication, perturbing replisome progression and leading to DNA damage. The synergistic effect of TOP1 and BRD4 inhibition is specific for cancer cells leaving normal cells unharmed, highlighting the sensitivity of the tumor to these transcriptional defects. This preclinical study provides a mechanistic understanding of the benefit of combining TOP1 and BRD4 inhibitors to treat pancreatic carcinomas addicted to oncogenic drivers of high transcription and replication. One Sentence SummaryTOP1 and BRD4 inhibitors synergize to selectively kill pancreatic cancer in vivo via readthrough transcription without emergence of drug resistance

cancer biology↗